Alder Biopharmaceuticals Inc., of Bothell, Wash., named Roger K. Cady vice president of neurology.
Ardelyx Inc., of Fremont, Calif., added Robert Bazemore to its board.
Biofrontera AG, of Leverkusen, Germany, added Mark Reeth, John Borer III, Kevin Weber and Hansjörg Plaggemars to its board and named Ulrich Granzer board chairman and Jürgen Baumann vice chairman.
Celyad SA, of Mont-Saint-Guibert, Belgium, appointed David Gilham vice president of research and development, effective Sept. 1.
DBV Technologies SA, of Montrouge, France, appointed Motohiro Ebisawa to its scientific advisory board.
Five Prime Therapeutics Inc., of South San Francisco, appointed Robert Sikorski chief medical officer.
Grunenthal Group, of Aachen, Germany, named Gabriel Baertschi CEO, effective Oct. 1.
H3 Biomedicine Inc., of Cambridge, Mass., named Tarek Sahmoud chief medical officer.
Laboratoris Sanifit S.L., of Palma de Mallorca, Spain, appointed Preston S. Klassen chief medical officer. Klassen will also serve as president of the company’s new U.S. subsidiary in San Diego, Sanifit Inc.
Miragen Therapeutics Inc., of Boulder Colo., named Adam Levy chief business officer, and Christopher J. Morl chief operating officer.